JP2021533181A5 - - Google Patents

Info

Publication number
JP2021533181A5
JP2021533181A5 JP2021518993A JP2021518993A JP2021533181A5 JP 2021533181 A5 JP2021533181 A5 JP 2021533181A5 JP 2021518993 A JP2021518993 A JP 2021518993A JP 2021518993 A JP2021518993 A JP 2021518993A JP 2021533181 A5 JP2021533181 A5 JP 2021533181A5
Authority
JP
Japan
Prior art keywords
uchl5
bifunctional molecule
target protein
binding partner
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021518993A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533181A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/065479 external-priority patent/WO2019238816A1/en
Publication of JP2021533181A publication Critical patent/JP2021533181A/ja
Publication of JP2021533181A5 publication Critical patent/JP2021533181A5/ja
Pending legal-status Critical Current

Links

JP2021518993A 2018-06-13 2019-06-13 UchL5を標的化するための二機能性分子 Pending JP2021533181A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862684268P 2018-06-13 2018-06-13
US62/684,268 2018-06-13
US201962835955P 2019-04-18 2019-04-18
US62/835,955 2019-04-18
PCT/EP2019/065479 WO2019238816A1 (en) 2018-06-13 2019-06-13 Bifunctional molecules for targeting uchl5

Publications (2)

Publication Number Publication Date
JP2021533181A JP2021533181A (ja) 2021-12-02
JP2021533181A5 true JP2021533181A5 (cg-RX-API-DMAC10.html) 2022-06-21

Family

ID=67105989

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021518993A Pending JP2021533181A (ja) 2018-06-13 2019-06-13 UchL5を標的化するための二機能性分子

Country Status (7)

Country Link
US (1) US20210283139A1 (cg-RX-API-DMAC10.html)
EP (1) EP3807263A1 (cg-RX-API-DMAC10.html)
JP (1) JP2021533181A (cg-RX-API-DMAC10.html)
KR (1) KR20210020107A (cg-RX-API-DMAC10.html)
CN (1) CN112585127A (cg-RX-API-DMAC10.html)
CA (1) CA3103205A1 (cg-RX-API-DMAC10.html)
WO (1) WO2019238816A1 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4090371A4 (en) * 2020-01-14 2024-04-03 The Trustees of Columbia University in the City of New York COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY RE-ROUTING ENDOGENOUS DEUBIQUITINASES
GB202102494D0 (en) * 2021-02-22 2021-04-07 Amphista Therapeurics Ltd Novel bifunctional molecules for targeted protein degredation
IL303717A (en) 2020-12-18 2023-08-01 Amphista Therapeutics Ltd Novel bifunctional molecules for targeted protein degradation
US20240024490A1 (en) * 2021-04-09 2024-01-25 The Broad Institute, Inc. Bifunctional molecules for selective modification of target substrates
CA3216614A1 (en) * 2021-04-29 2022-11-03 Lydia BOIKE Deubiquitinase-targeting chimeras and related methods
JP2025525347A (ja) 2022-06-16 2025-08-05 アンフィスタ セラピューティクス リミテッド 標的タンパク質分解のための新規の二官能性分子
WO2023242598A1 (en) 2022-06-16 2023-12-21 Amphista Therapeutics Limited Bifunctional molecules for targeted protein degradation
AU2023343029A1 (en) 2022-09-13 2025-03-27 Amphista Therapeutics Limited Compounds for targeted protein degradation
AU2023358062A1 (en) 2022-10-07 2025-03-20 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
WO2024127297A1 (en) 2022-12-16 2024-06-20 Pfizer Inc. 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof
CN121752561A (zh) * 2023-07-26 2026-03-27 先声再明医药股份有限公司 用于靶蛋白降解的化合物
AU2024395784A1 (en) 2023-12-07 2026-06-11 Pfizer Inc. Biphenyl and phenylpyridine compounds as inhibitors of kat2a and/or kat2b
GB202319256D0 (en) 2023-12-15 2024-01-31 Amphista Therapeutics Ltd Novel compounds for targeted protein degradation
WO2025221154A1 (en) 2024-04-17 2025-10-23 Captor Therapeutics S.A. Klhdc2 (kelch domain-containing protein 2) ligase ligands
WO2026052822A1 (en) 2024-09-06 2026-03-12 Amphista Therapeutics Limited Tetrahydroisoquinoline compounds for targeted protein degradation
WO2026088071A1 (en) 2024-10-23 2026-04-30 Pfizer Inc. Substituted fused heteroaryl lactam compounds
WO2026154417A1 (en) 2025-01-17 2026-07-23 Pfizer Inc. Fused heterocyclic amide/sulfonamide compounds as agonists of the calcitonin/amylin receptors for the treatment of obesity
WO2026159633A1 (en) 2025-01-24 2026-07-30 Pfizer Inc. 4-(2-(dimethylamino)-2-oxoethyl)-3-methyl-5-oxo-2,3,4,5-tetrahydrobenzofuro[2,3-f][1,4]oxazepine-3-carboxamide compounds and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
CA2366932C (en) * 1999-04-15 2009-08-25 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
ZA200800314B (en) 2005-06-29 2009-09-30 Threshold Pharmaceuticals Inc Phosphoramidate alkylator prodrugs
RU59063U1 (ru) 2006-05-30 2006-12-10 Государственное образовательное учреждение высшего профессионального образования "Ульяновский государственный технический университет" Режущий инструмент с многослойным покрытием
US8552048B2 (en) 2006-12-26 2013-10-08 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs for the treatment of cancer
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
JP5852658B2 (ja) * 2010-09-24 2016-02-03 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン デユビキチナーゼ阻害剤およびその使用方法
EP2649099A4 (en) 2010-12-07 2016-10-19 Univ Yale SMALL MOLECULAR HYDROPHOBIC LABELING OF FUSION PROTEINS AND INDUCED REMOVAL FROM THIS
KR102438072B1 (ko) 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
US20170095457A1 (en) * 2014-05-27 2017-04-06 David Lonergan Compositions and methods of delivery of deubiquitinase inhibitors
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
GB201504314D0 (en) 2015-03-13 2015-04-29 Univ Dundee Small molecules
CA2994969A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
WO2017024317A2 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
BR112018008918A8 (pt) * 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
GB2554071A (en) * 2016-09-14 2018-03-28 Univ Dundee Small molecules

Similar Documents

Publication Publication Date Title
JP2021527137A5 (cg-RX-API-DMAC10.html)
JP2018535925A5 (cg-RX-API-DMAC10.html)
CN101657454B (zh) 18f-标记的叶酸类
CN110087649A (zh) 用辛伐他汀和化疗药物与七甲川花菁染料偶联体提高肿瘤对激素拮抗剂和药物的敏感性
JP2012102106A5 (cg-RX-API-DMAC10.html)
Xu et al. A far-red-emissive AIE active fluorescent probe with large stokes shift for detection of inflammatory bowel disease in vivo
KR20240151869A (ko) Enpp1 저해제 및 암의 치료용의 이의 용도
JP2021513968A5 (cg-RX-API-DMAC10.html)
JP5897461B2 (ja) ミエリン塩基性タンパク質のイメージング
KR20230154183A (ko) 화합물 및 방사성 표지 화합물
KR20160074683A (ko) 18f-표지된 폴레이트
Hübner et al. Functional Hybrid Molecules for the Visualization of Cancer: PESIN‐Homodimers Combined with Multimodal Molecular Imaging Probes for Positron Emission Tomography and Optical Imaging: Suited for Tracking of GRPR‐Positive Malignant Tissue
JP2024528602A (ja) イメージングの為の、標識化された化合物カルシウム感知受容体リガンド、並びにそれらの使用方法
CN114729938B (zh) 发光化合物
Basuli et al. A first synthesis of 18F‐radiolabeled lapatinib: a potential tracer for positron emission tomographic imaging of ErbB1/ErbB2 tyrosine kinase activity
US20090004107A1 (en) Beta-amyloid and neurofibrillary tangle imaging agents
KR102228460B1 (ko) Cox2 과발현 질환 진단용 조성물 및 이의 스크리닝 방법
CN120136958A (zh) Fap靶向放射性药物
Wang et al. Rational design of pyridinium styryl derivatives as PET tracers for cardiac amyloidosis imaging
CN103391789A (zh) 成像剂
Mudd et al. Hybrid PET/CT for noninvasive pharmacokinetic evaluation of dynamic PolyConjugates, a synthetic siRNA delivery system
US7943775B2 (en) Small molecules for imaging protein-protein interactions
CN101293878A (zh) 苯并噻唑苯胺类化合物及其制备方法和应用
WO2012121285A1 (ja) 標識前駆体化合物、放射性標識化合物、及びそれらの製造方法
JP7834363B2 (ja) トレーサー化合物およびその調製方法